PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(02): 4-5
DOI: 10.1055/s-0041-1733209
Editorial

Oral Antibiotic Therapy for Low Risk Febrile Neutropenia: Time to Dare

Ashish Dixit
Department of Clinical Hematology & Blood & Bone Marrow Transplant Comprehensive Cancer Centre Manipal Hospital, Bangalore, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
07. März 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Klasterky J, Paesman M, Rubenstein EB et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low risk febrile neutropenia. J Clin Oncol 2000;18:3038-51.
  • 2 Hughes WT, Armstrong D, Bodey GP et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
  • 3 Klaasseen RJ, Goodman R, Pham BA, Doyle JJ. Low-risk prediction rule for pediatric oncologypatients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012-9.
  • 4 Vidal L, Paul M, Ben dor I et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrobial Chemotherapy 2004;54:29.
  • 5 Dominic JF, Kumar L, Kochupillai V et al. A randomized, prospective open label study of oral amoxicillin-clavulanate and levofloxacin with intravenous ceftriaxone and amikacin in chemotherapy induced low risk febrile neutropenia. Ind J Med & Paed Oncol. 2007;28:7-15.